New hope for advanced HER2 cancers? drug trial launches
NCT ID NCT07631871
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests a drug called zanidatamab in 10 adults with advanced HER2-positive solid tumors (like endometrial, bladder, or pancreatic cancer) that have worsened after at least one prior treatment. Participants receive the drug by IV every two weeks. The main goal is to see how many patients' tumors shrink or disappear. This is not a cure, but aims to control the disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL NEOPLASMS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a simple blood test spot ovarian cancer before it starts?
- A simple screening program could transform cancer aftercare
- Can a Dual-Pronged antibody outsmart advanced solid tumors?
- Can a new infusion drug shrink Hard-to-Treat tumors?
- Can delivering cancer drug directly to the liver shrink tumors?
- A new program aims to ease the 'Lost in Transition' struggle for cancer survivors